Purpose of Review In this review, we synthesize current data on non-adherence across inflammatory arthritides and explore (1) the effects of economic factors on non-adherence and (2) the impacts of non-adherence on economic outcomes. Recent Findings Recent evidence demonstrates medication non-adherence rates as high as 74% in ankylosing spondylitis (AS), 90% in gout, 50% in psoriatic arthritis (PsA), 75% in systemic lupus erythematosus (SLE), and 82% in rheumatoid arthritis (RA). Summary The effects of socioeconomic factors have been studied most in RA and SLE but with inconsistent findings. Nonetheless, the evidence points to having prescription coverage and costs of treatment as important factors in RA and education as an important factor in SLE. Limited data in AS and gout, and no studies of the effects of socioeconomic factors in PsA, show knowledge gaps for future research. Finally, there is a dearth of data with respect to the impacts of nonadherence on economic outcomes.
Introduction
For many patients living with lifelong diseases, managing conditions and taking medications as prescribed (adherence) is a challenge. Because patients rely on medications to relieve symptoms, continue participation in daily life activities, and prevent the worsening of disease, medication non-adherence is especially problematic in inflammatory arthritis-a group of conditions that includes ankylosing spondylitis (AS), gout, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). Evidence synthesis including those in gout [1•], SLE [2•] , and RA [3-6, 7•] shows that adherence is suboptimal across many of these conditions. Also alarming is the impact of non-adherence on patient outcomes, such as increased hospitalizations and emergency department visits in SLE [8, 9] , elevated serum uric acid levels in gout [10] , and disease flares in RA [11] .
Given the growing epidemic of non-adherence in inflammatory arthritides and the high costs of medications used to treat many of these conditions, particularly biologics, it is important to have a better understanding of associated economic issues. In our view, there is a duality of these issues as follows: (1) the effects of economic factors on non-adherence and (2) the impacts of non-adherence on economic outcomes. Specifically, as one of the World Health Organization's five dimensions of adherence, socioeconomic factors may have an effect on nonadherence through various mechanisms including affordability (e.g., cost of medications), access (e.g., having prescription coverage), or understanding of the medications and their use (e.g., low education level) [12] . In 2013, Kardas et al. compiled findings across 51 systematic reviews on determinants of non-adherence to develop a taxonomy of factors for each of the World Health Organization's five dimensions [13] . According to this taxonomy, socioeconomic factors include family support (e.g., family support in executing medication), family/caregiver factors (e.g., number of people in the household), social support, and social stigma of a disease, as well as those that are of particular relevance to our review-costs of drug and/or treatment, prescription coverage, socioeconomic status, education, and employment status [13] .
The other side of the issue are the economic consequences of non-adherence. In their 2014 review, Iuga and McGuire described a conceptual mechanism of how non-adherence compromises the effectiveness of treatment and leads to adverse health outcomes, thus increasing health-care utilization and costs [12, 14] . As such, there is a potential economic impact of non-adherence on the health-care sector, patient and family, as well as other sectors. Figure 1 provides a conceptual framework of the duality of economic issues when considering non-adherence. Guided by this framework, our objective is to provide a synthesis of the current research on the burden of non-adherence in inflammatory arthritides as well as associated economic issues. While we focused our review on the literature published in the past 5 years, in cases of limited data, we extended beyond this period.
Understanding Medication Non-adherence
In keeping with calls in the literature to standardize the nomenclature of medication non-adherence [15] [16] [17] , we outline the relevant definitions. Specifically, the term "medication non-adherence" can refer to either (1) poor execution or implementation of the prescribed treatment recommendation, leading to omitted or delayed doses which may interrupt drug action, or (2) stopping or discontinuation of the prescribed treatment, leading to transient or permanent interruption of drug action [18, 19] . Medication persistence refers to the act of continuing treatment for the prescribed duration and is reciprocal to discontinuation [15] .
Also relevant to our review is drug survival-defined as the length of time from initiation to discontinuation of a particular treatment [20] -as it has been used to describe patterns of use of biologics in RA over the past several years and, more recently, in AS and PsA. In this context, drug survival (as well as related terms "treatment retention" and "treatment continuation") is an alternative way to describe persistence and could therefore be considered as another measure of adherence [21] . However, some scholars argue that the term "drug survival" excludes additional factors encompassing the complexity of adherence such as the determinants of adherence and patient attitudes and beliefs [22] . However, many argue that drug survival can be used as a general marker of treatment success which encompasses various components of patient adherence, side effects, and drug efficacy [23] . A final consideration is the directionality of reporting, that is, whether studies centered on adherence (i.e., having good behavior or outcome) or nonadherence, which has implications for consistency. For our purposes, we centered our review on non-adherence and, when feasible, converted and/or translated findings from included studies that have centered on adherence.
Ankylosing Spondylitis
Affecting 0.1 to 1.4% of the population [24, 25] , AS is characterized by inflammatory back pain, progressive bony fusion of the vertebrae, and arthritis in the hips, shoulders, or peripheral joints [24] . Eighty percent of cases present before 30 years of age and less than 5% after 45 years [26] . According to recommendations of the Assessments in Ankylosing Spondylitis International Society and European League Against Rheumatism (EULAR), the primary goal of AS treatment is to maximize health-related quality of life through control of symptoms and inflammation, prevention of progressive structural damage, and normalization of function [27] . Nonsteroidal anti-inflammatory drugs (NSAIDs) as a first-line therapy for pain and stiffness and physical therapy are mainstay treatment approaches in AS [28] . Recently, treatment recommendations from the American College of Rheumatology (ACR) include the use of tumor necrosis factor (TNF) inhibitors [29] .
Few studies have evaluated the burden of non-adherence to medication in AS. The earliest study was in 1996 by De Klerk and Van der Linden in the Netherlands which revealed low rates of NSAID non-adherence in 65 AS patients (20%) using electronic monitoring devices [30] . The introduction of biologics led to studies of non-adherence with these agents in AS, including a 2006 Spanish study [31] , a 2008 Norwegian study [32] , and a 2009 Czech study [33] . In 2013, a study from Argentina by Arturi et al. showed that non-adherence to pharmacological treatments (including NSAIDs, diseasemodifying antirheumatic drugs (DMARDs), and biologics) in 59 AS patients was 25.4% based on self-reported questionnaires [34] . However, more recent reports have reported higher non-adherence rates among AS patients. Betegnie et al.'s 2016 study from France used a questionnaire to understand why AS patients decide to discontinue biologic treatment. In this study, 74% of 351 AS patients discontinued their biologics at least once [35] . Among these, 20% of discontinuations were the patients' decision with reasons including low level of pain, self-administration of biologics, negative beliefs about treatment, and lack of medical and social support. Finally, Lyu et al.'s 2016 study from Germany used electronic medical records to study persistence to subcutaneous biologic therapies among patients with rheumatic disease including 108 patients with AS [36] . They reported 1-year discontinuation of 51.9% with mean treatment duration of 228.5 days [36] .
As with the burden of non-adherence, data on the economics of non-adherence in AS is very limited. We identified a single 2013 study by Arturi et al. on the effects of economic factors on non-adherence, which primarily used self-reported questionnaires including the Compliance Questionnaire Rheumatology (CQR) to identify factors associated with non-adherence among 59 patients with AS in Argentina [34] (Table 1) . While they observed a lower number of years of education among nonadherent patients compared to adherent patients, this was not statistically significant (11.4 ± 4 vs. 12.4 ± 4 years, p value > 0.05) [34] . Interestingly, a higher proportion of non-adherent patients reported having health insurance compared to adherent patients; however, this was also not statistically significant (72.7 vs. 53.5%, p value > 0.05) [34] . Finally, there were no studies that have directly evaluated the economic impacts of treatment non-adherence in AS. Nonetheless, a 2009 cohort study of 310 AS patients in Argentina by Pavelka et al. reported that the proportion of fully employed patients increased from 48% at baseline to 63% after 1 year of therapy with anti-TNF agents [33] (Table 2) .
Gout
Gout is the most common inflammatory arthritis that affects up to 3.8% of adults [37] and develops due to an excess of serum uric acid (SUA) levels which results in the formation of monosodium urate crystals [38] and, if left untreated, can cause severe inflammatory response leading to joint destruction [1•]. In addition, the disease is complicated by substantial cardiovascular, metabolic, and renal comorbidities [39] . Both acute and chronic manifestations of gout are caused by deposition of monosodium urate crystals [38] , and as such, eliminating urate crystals by reducing urate levels essentially cures the disease. The ACR [40] and EULAR [41] recommend the use of urate-lowering therapies (such as allopurinol) as well as uricosuric agents for the management of gout.
Medication non-adherence in gout has been well described. In 2013, we published a systematic review investigating the burden, predictors, and impacts of non-adherence in gout [1•]. We identified 16 studies which used various methods of measuring non-adherence. Overall, the proportion of non-adherent gout patients ranged from 54 to 90%, highlighting that nonadherence is a significant problem in gout. Among included studies, older age, as well as having comorbid hypertension, was consistently shown to be positively associated with better adherence [1•]. In 2016, a retrospective study using a national administrative pharmacy claims database in Ireland demonstrated that, for all gout patients initiating urate-lowering therapies, 54.2% of patients discontinued treatment within 6 months [42] . Indeed, these consistent reports of suboptimal treatment adherence in gout are alarming, especially given the contribution of non-adherence to disease outcomes [43] .
Despite the number of studies on the burden of nonadherence in gout, very few have reported on the effects of economic factors on non-adherence in gout or the economic impacts of non-adherence in gout. With respect to the former, in 2013, Zandman-Goddard et al. used administrative data from a health maintenance organization in Israel to identify predictors of non-adherence with allopurinol [44] . Among these factors was socioeconomic status which was categorized into quintiles according to a poverty index that was based on household income, educational qualifications, crowding, material conditions, and car ownership [44] . Compared to the reference category or the 3rd quintile, individuals in the 1st quintile (lowest SES) had a 21% higher odds ratio of being non-adherent (odds ratio (OR), 1.21; 95% CI, 1.03-1.42) and those in the 5th quintile (highest SES) had a 61% lower odds ratio of being non-adherent (OR, 0.39; 95% CI, 0.32-0.46) [44] . Finally, we could not identify any study that has directly evaluated the economic impacts of treatment non-adherence in gout. Nonetheless, a study that has shown an indirect relationship is one by Halpern et al.'s 2009 cohort study which used administrative databases for a managed health-care plan in the USA. Specifically, authors first showed the relationship of a lower proportion of individuals non-adherent to allopurinol therapy (having medication possession ratio < 0.80) achieving target serum uric acid level (< 6.0 mg/dL) across three time periods: 27.8% non-adherent vs. 49.3% adherent a Centered on non-adherence for purposes of this review, and as such, any studies reporting on adherence were converted/translated b Not a direct study of economic impact of non-adherence and not feasible to convert/translate but, nonetheless, included given limited data c Not a direct study of economic impact of non-adherence, but in the same paper, authors showed the relationship between adherence and SUA levels which could then be extrapolated to SUA levels and gout-related health costs in period 1, 22.5 vs. 51.8% in period 2, and 23.8 vs. 56.8% in period 3 []. Afterwards, in both unadjusted and adjusted analyses, authors showed the relationship between lower serum uric acid levels and gout-related health-care (including medical claims for office visits, outpatient hospital visits, emergency department visits, and inpatient hospitalizations) costs []. Specifically, median costs for corresponding serum uric acid levels were $167, $196, and $222 for < 6.0 mg/dL, between 6.0 and 9.0 mg/dL, and ≥ 9.0 mg/dL, respectively. Multivariable models show that compared to individuals at the lowest serum uric acid level, gout-related health-care costs for those at the highest serum uric acid level were 1.6 times higher (exponentiated coefficient, 1.576; 95% CI, 1.02-2.46).
Psoriatic Arthritis
PsA is a chronic, seronegative inflammatory arthritis associated with psoriasis, a chronic autoimmune inflammatory skin disease [45] . Estimated prevalence rates of PsA range from 0.04 to 0.1% [46] . According to the recommendations for the pharmacological management of PsA by the EULAR, the goals of treatment are to maximize the quality of life through control of symptoms, as well as prevention of structural damage and normalization of function and social participation through control of inflammation [47] . Recommendations include the use of traditional DMARDs as an initial therapy followed, if necessary, with biologics [47] .
Similar to AS, data on medication adherence in PsA is still emerging. However, the development of biologics, particularly anti-TNF therapies, has dramatically improved the management PsA, and several reports have examined non-adherence-largely, discontinuation of these therapies among patients. Prior studies including a Spanish study in 2006 [31] , a Norwegian study in 2008 [32] , and a UK study in 2009 [48] reported discontinuation rates ranging from 12 to 24.5% at 1 year with the most cited reasons for discontinuation as a lack of efficacy and adverse events. In 2012, Chastek et al. used administrative data in the USA and reported that among 346 PsA patients, approximately half discontinued their index anti-TNF therapy within 1 year. Pauses in therapy and therapy discontinuation were common, but more than 40% of patients restarted their index anti-TNF after discontinuation [49] . Finally, Lyu et al.'s 2016 study in Germany using an electronic medical record database including 197 PsA patients found that 42.1% of patients discontinued their anti-TNF therapies within 1 year with mean treatment duration of 264.1 days [36] .
We could not identify any studies on the effects of economic factors on non-adherence in PsA or the economic impacts of non-adherence in PsA.
Systemic Lupus Erythematosus
SLE is a chronic systemic autoimmune rheumatic disease that specifically attacks collagen and results in multifarious clinical manifestations including joint pain, photosensitivity, malar rash, and clinical nephritis [50, 51] . It occurs predominantly in women (approximately 9:1 female-to-male ratio) during their childbearing years [52] , with reported prevalence of 143.7 per 100,000 and incidence of 23.2 per 100,000 person-years [53] . As there is no cure for SLE, the goals of treatment include decreasing autoimmunity to slow down disease progression and prevent damage to other organ systems from the downstream effects of SLE [52] . The conventional option to achieve these goals among patients with SLE with minimal organ involvement is the long-term use of antimalarials, namely hydroxychloroquine and chloroquine [54, 55] . It is recommended that SLE patients with multiple organ systems involved should additionally be taking other immunosuppressive medications (azathioprine, cyclophosphamide, methotrexate, chlorambucil, and cyclosporine) [54, 55] .
Similar to gout, medication non-adherence has been well described in SLE. In 2008, Harrold and Andrade published a systemic review of medication non-adherence in selected rheumatic diseases which included four papers in SLE [56] . However, reported non-adherence rates were largely inconsistent. Updating this data, in 2017, we published a systematic review to investigate the burden and predictors of nonadherence in SLE and identified 11 studies which used various methods of measuring adherence. The percentage of nonadherent SLE patients ranged from 43 to 75%, studies consistently reporting that over half of patients are non-adherent [2•]. Furthermore, in this systematic review, we identified determinants of non-adherence including having depression and polypharmacy [2• ].
There are a few studies on the effects of economic factors on non-adherence in SLE, and as such, we have included both earlier and more current studies in our review. Four studies including two in the USA [57, 58] , one in Brazil [59] , and one in Egypt [60] reported on the effect of education, albeit operationalized differently. For example, in a cross-sectional study of 32 patients with SLE in the USA, Garcia-Gonzalez et al. reported a positive correlation between education (categorized as less than high school, high school, college, Bachelor's degree, advanced degree) and adherence as measured by the CQR (r = 0.31; p < 0.01) [57] . Using a combination of selfreported questionnaire, chart review, and patient interviews, Oliveira-Santos et al. evaluated a variety of factors associated with medication non-adherence among 246 women with SLE in Brazil. In this sample, 37.8% had completed secondary education and the variable "schooling" was shown to have a negative association with adherence to SLE treatment (OR, 0.46; 95% CI, 0.21-1.00) in the final multivariable model; however, authors did not indicate the reference category, limiting interpretation. Interestingly, a finding of this study were reasons individuals cited for having difficulty in "taking their medicines" which, for our purposes, may signal nonadherence, which include lack of money to purchase the medicine (52.4% of patients) and failure to receive the medicine free of cost from the Unified National Health System (6.4% of patients). In Egypt, Koneru et al. evaluated determinants of non-adherence in 80 patients with SLE and reported that compared to individuals with > 12 years of education, those with ≤ 12 years had a fourfold OR (4.2; 95% CI, 1.6-8.4) of being non-adherent as measured by the CQR [58] . In this study, authors also assessed socioeconomic status using a validated scale for health research in Egypt and showed that compared to patients at moderate and high status, those with very low and low socioeconomic status had 3.5 times the odds ratio of being non-adherent (OR, 3.5; 95% CI, 1.6-7.9). Finally, in a recent study in 2016 of 92 patients with SLE in Brazil, Prudente et al. showed that acquisition of medications at a high-cost pharmacy is more likely to be adherent (OR, 5.95; 95% CI, 1.02-34.69) [61] .
Only two studies evaluated the economic impacts of nonadherence in SLE. In a 2009 cohort study of 834 patients with SLE in the USA, Julian et al. showed that those with selfreported unintentional adherence had increased numbers of rheumatology visits, primary care visits, emergency department visits, and hospitalizations and were more likely to visit the emergency department (OR, 1.45; 95% CI, 1.04-2.04) as compared to patients who did not report adherence difficulties [9] . Using the US Medicaid data in 2015, Feldman et al. showed that among SLE patients on hydroxychloroquine, those who were classified as non-adherent (based on medication possession ratio (MPR) < 80%) had higher incidence of SLE-related emergency department visits (incidence rate ratio (IRR) 1.60; 95% CI, 1.43-1.80) and SLE-related hospitalizations (IRR, 1.30; 95% CI, 1.18-1.44) compared to those classified as adherent [8] . Similarly, among SLE patients on immunosuppressive medications, those who were classified as non-adherent had higher incidence of SLE-related emergency department visits (IRR, 1.69; 95% CI, 1.38-2.05) and SLErelated hospitalizations (IRR, 1.60; 95% CI, 1.34-1.91) [8] .
Rheumatoid Arthritis
RA is a chronic autoimmune disease characterized by joint inflammation with pain, swelling, damage, and disability. RA affects approximately 1% of the population with an increased prevalence in women and the elderly [62] . Current guidelines recommend treating the majority of RA patients with DMARDs in order to control symptoms, induce disease remission, and prevent disability [63, 64] . Adherence to these prescribed drugs is essential in order to prevent irreversible joint damage [65] [66] [67] [68] [69] [70] . For patients with high disease activity or a suboptimal response to DMARDs, better disease control may be achieved by switching or adding a biologic agent to their therapeutic regimen [63, 64] .
Among inflammatory arthritides, the burden of therapy non-adherence has been best described in RA with earlier syntheses including a systematic review in 2009 by Harrold and Andrade [] and two reviews in 2010 by de Achaval and Suarez-Almazor [71] and Salt and Frazier [3] -all based on DMARDs. Various adherence measures were used across studies, but nonetheless, reported non-adherence rates as high as 70% signal an important therapeutic challenge in RA. With respect to biologics, prior systematic reviews by Koncz et al. in 2010 [21] and Blum et al. in 2011 [72] similarly concluded that non-adherence to biologic therapies in RA is a problem. More recently, in 2012, van den Bemt et al. published a critical appraisal of the literature on non-adherence to both DMARDs and biologics, reporting rates ranging from 20 to 70% [6] . In 2014, we published a review of the economics of nonadherence to biologics in patients with RA which included a synthesis of non-adherence rates which ranged from 13 to 76% among studies that explicitly evaluated adherence Table 3 Number of studies reporting association between socioeconomic factors and non-adherence in rheumatoid arthritis from prior reviews
Socioeconomic factor
De Achaval and SuarezAlmazor [71] van den Bemt et al. [6] Pasma et al. (n = 7) and 20 to 82% among studies that evaluated drug survival (n = 16) [5] . In this synthesis of the evidence, we observed that etanercept had the highest persistence rates, in general, compared to infliximab and adalimumab [5] .
As with the burden of non-adherence, the effect of various economic factors on non-adherence in RA has been evaluated in a number of studies and synthesized in aforementioned reviews [4] [5] [6] 71] . We tabulated findings from these prior reviews as the number of studies that have reported a lack of an association or an association with various socioeconomic factors and non-adherence (Table 3) . Data on socioeconomic status, employment status, and education are inconsistent; for example, in their review in 2012, van den Bemt et al. identified five studies that have reported a lack of association of education with non-adherence but also three studies that have reported an association [6] . Having prescription coverage was the only factor that was consistently shown to have an association with non-adherence across reviews.
Studies exploring the relationship between economic outcomes and medication non-adherence in RA are limited. A study by Tang et al. in 2009 compared treatment persistence in patients taking anti-TNF therapies (adalimumab, etanercept, or infliximab) in combination with methotrexate and the effects of persistence on overall health-care costs [73] . Across patients, those with treatment persistence greater than 80% (persistent) had higher mean total health-care costs compared with those with treatment persistence less than 80% (non-persistent), largely driven by pharmacy costs. However, non-pharmacy costs including inpatient, other outpatient, and laboratory services were lower in the first cohort. Importantly, emergency department costs and inpatient services were reduced by over 60% among persistent patients. Finally, persistence with medication was associated with lower health-care costs, lower comorbidity levels, and lower disease-stage score. Also in the USA, Borah et al. found that total health-care costs were higher among RA patients who were adherent to their subcutaneous anti-TNFs compared to those who were non-adherent; however, adherent patients had fewer ambulatory, emergency room, and inpatient visits compared to nonadherent patients [74] . Finally, a 2017 report from the Netherlands by Pasma et al. explored the relation between nonadherence to DMARDs and health-care costs in a group of 206 patients, 74.2% of which had RA, 20.9% PsA, and 4.9% undifferentiated arthritis [75] . Their study demonstrated that as the percentage of adherent patients decreased from 100 to 60% (40% of the amount of medication not taken), the mean healthcare costs (including costs for comorbidities, referrals, anti-TNF therapies, synthetic DMARDs, and rheumatology outpatient clinic as measured by hospital files) increased. Furthermore, in multivariable models, authors showed the statistically significant associations between non-adherence and rheumatology outpatient clinic costs, rheumatology-related costs, and total hospital costs. This was the first study of its kind to demonstrate that nonadherence is associated with hospital health-care costs in the first year of treatment for arthritis patients. Beyond hospital files, however, economic impacts excluded from the study encompass medical costs made outside the hospital, travel costs, and costs of productivity loss.
Discussion
In this review, we synthesized current data on nonadherence across inflammatory arthritides-confirming that non-adherence is indeed suboptimal in gout, SLE, and RA-diseases where it has been well described, and highlighted emerging evidence for less-studied diseases of AS and PsA. The effects of socioeconomic factors have been studied most in RA and SLE but with inconsistent findings. Nonetheless, the evidence points to having prescription coverage and costs of drug/treatment as important factors in RA and education as an important factor in SLE. Limited data in AS and gout, with only one study identified for each, and no studies of the effects of socioeconomic factors in PsA show knowledge gaps for future research. Perhaps, one of the key findings of our review is limited data across inflammatory arthritides on the impacts of non-adherence on economic outcomes. Indeed, a comprehensive understanding of the burden of nonadherence in inflammatory arthritis also needs to consider its impacts particularly on costs to the patient, the healthcare system, and the society. This systematic review synthesized empirical evidence on the burden, predictors, and impacts of non-adherence in gout.
